Study on the Reduction of Catheter-related Infections by Use of Self-disinfecting Venous and Arterial Access Caps
Completed
- Conditions
- Catheter-Related Blood Stream InfectionCLABSI - Central Line Associated Bloodstream Infection
- Registration Number
- NCT04534348
- Lead Sponsor
- University of Cologne
- Brief Summary
Observational study on the reduction of catheter-related Infections by use of self-disinfecting venous and arterial access caps (Curos caps ;3M, Saint Paul, MN, USA)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 598
Inclusion Criteria
- every patient in the hemato-oncological department who received at least one CVC was included in the study
Exclusion Criteria
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of CLABSI 12 Months To assess the clinical efficacy of Curos in preventing CLABSI in a high-risk department (oncology and ICU)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 70% isopropyl alcohol-impregnated catheter caps in preventing CLABSI?
How do self-disinfecting catheter caps compare to chlorhexidine-impregnated caps in reducing catheter-related bloodstream infections?
Which biomarkers correlate with CLABSI risk reduction in patients using 3M Curos alcohol-impregnated caps?
What adverse events are associated with 70% isopropyl alcohol-impregnated catheter caps in clinical practice?
What are the antimicrobial resistance implications of 3M Curos caps versus silver-coated catheter devices in NCT04534348?
Trial Locations
- Locations (1)
University Hospital of Cologne
🇩🇪Cologne, Germany
University Hospital of Cologne🇩🇪Cologne, Germany